ADC Development for Melanoma

Melanoma is the most aggressive and the deadliest cancer arising from skin. Traditional therapeutic options such as the surgical resection or chemotherapy represent major approaches. However, the therapy efficiency of these therapies remains weak due to the development of diverse resistance mechanisms. Thus, new therapeutic agents are needed to improve the outcome. Nowadays, antibody-drug conjugates (ADCs) emerged as a promising therapy for the treatment of melanoma.

Creative Biolabs is committed to providing high-quality and fast-delivering custom ADCs services to support client's drug development program. Through the method of covalent linkage, antibodies can be efficiently attached to the payload. Relying on the state-of-the-art facilities, our one-stop ADCs development targeting melanoma will be meticulously monitored and controlled to ensure that the quality of thwe final products.

Introduction of Melanoma

Melanoma is a type of cancer occurring in the skin, eye, inner ear, and leptomeninges, which is the most serious skin cancer. The signs and symptoms of melanomas often include a change of an existing mole, a new pigmented or unusual-looking growth on the skin, such as an increase in size, irregular edges, change of mole color, itchiness, or skin breakdown. The main cause of most of the cancer cases is the exposure to ultraviolet (UV) radiation from the sun and from tanning lamps and beds. Other melanoma cases occur in the body that don't receive exposure to UV light mainly attribute to some risk factors including fair skin, a history of sunburn, excessive ultraviolet (UV) light exposure, living closer to the equator or at a higher elevation, having many moles or unusual moles, a family history of melanoma and weakened immune system. Currently, the treatment options for the melanoma include surgery to remove affected lymph nodes, chemotherapy, radiation therapy, biological therapy and targeted therapy.

Different stages of melanoma progress. Fig.1 Different stages of melanoma progress.

Current Therapeutic Strategies for Melanoma

To date, several therapeutic options for melanoma have been approved by the FDA including the surgical resection, chemotherapy, radiotherapy, photodynamic therapy (PDT), immunotherapy, and targeted therapy. Chemotherapy is the earliest treatment option for advanced melanoma, including dacarbazine (an alkylating agent), TMZ (an oral prodrug of the dacarbazine) and Electrochemotherapy (ECT). For patients with stage I–IIIB melanoma, surgery is the main treatment approach.

Immunotherapy is another promising treatment option for patients with advanced-stage (metastatic) malignant melanomas. Immunotherapy generally include interferon (IFN) α-2b, peginterferon α-2b (Peg-IFN), interleukin-2 (IL-2), Treg inhibition, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade, Programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) blockade, Oncolytic virus therapy, gp100 Peptide vaccine, toll-like receptor (TLR) agonists, and adoptive T-cell therapy. Besides, the combination of chemotherapy and immunotherapy (BCT) is also used in the melanoma treatment showing a higher response rate.

Most of cutaneous melanomas are associated with the mutations in genes of key signaling pathways. Thus, targeted therapy represents a novel therapeutic strategy is widely applied in the cancer therapy, such as the BRAF inhibitors, MEK inhibitors, CKIT inhibitors, VEGF inhibitors, PI3K-AKT-mTOR pathway inhibitors, Cyclin-dependent kinase (CDK) inhibitors and ErbB4 inhibitor. In addition, ADCs are a new therapy method that have been designed for targeted melanoma treatment. RG7636 (also known as DEDN6526A) is an ADC targeting the melanoma composed of a specific antibody and a potent drug. This ADC showed effective antitumor activity in preclinical study and is investigated in clinical phase I currently.

Targeted therapies approved by FDA or in trials for cutaneous melanoma treatment. Fig.2 Targeted therapies approved by FDA or in trials for cutaneous melanoma treatment. (Domingues, 2018)

What Can We Do for You?

Creative Biolabs specializes in the design and development of targeted drug against cancer diseases and offers a wide range of ADC development services. With the strength of our one-stop service platform covering antibody production, drug synthesis and bioconjugation, Creative Biolabs will continue help our global partners develop effective ADCs to benefit cancer patients worldwide. At present, we offer comprehensive ADCs construction services against melanoma.

Target of ADC development for melanoma:

ETBR

If you are interested in our services, please feel free to contact us for more detailed information.

Reference

  1. Domingues, B.; et al. Melanoma treatment in review. Immuno Targets and therapy. 2018, 7: 35.


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
USA
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
 Email:
Europe
Heidenkampsweg 58, 20097 Hamburg, Germany
 Tel: 44-207-097-1828
 Email:

Inquiry

Top